Is the flu shot worth it?
The flu vaccine gets 40–60% effectiveness headlines every year, and critics use that number to argue it's not worth the bother. Those critics are measuring the wrong thing. Here's an honest accounting of what the vaccine actually does — and for whom the benefit is most significant.
What "40–60% effective" actually means
Vaccine effectiveness (VE) measures how much the vaccine reduces the risk of getting flu severe enough to seek medical care. A VE of 50% means vaccinated people are half as likely to end up at the doctor with flu compared to unvaccinated people — not that the vaccine fails half the time.
That number varies considerably by season. In years when the vaccine strains closely match the circulating strains, effectiveness can reach 60–70%. In mismatch years — when the dominant strain drifts after the vaccine is formulated — effectiveness can drop to 20–30%. The CDC estimates seasonal VE each year based on surveillance data from the US Flu VE Network.
The 40–60% figure is a reasonable average across seasons and age groups. But focusing on it alone misses the more important question: effective at preventing what, exactly?
Prevention of illness vs. prevention of serious outcomes
The VE numbers cited in headlines measure protection against any medically attended flu illness. The vaccine's protection against serious outcomes — hospitalization, ICU admission, and death — is substantially stronger and more consistent across seasons.
The pattern makes biological sense: even partial immunity can fail to prevent infection but still prime the immune system to respond faster and more aggressively when infection occurs — limiting viral replication, reducing spread to the lungs, and preventing the cascade that leads to hospitalization.
Even when it doesn't prevent illness, it reduces severity
This is the most underappreciated point in the "is it worth it" debate. Studies consistently show that vaccinated people who still get flu tend to have shorter illness, lower peak fever, lower rates of pneumonia, and lower hospitalization rates than unvaccinated people who get the same strain.
A vaccine that doesn't fully prevent infection but reliably reduces a seven-day illness to four days, and keeps you out of the hospital when an unvaccinated person with the same exposure would need admission, is doing meaningful work — even if it doesn't show up cleanly in VE headlines.
Who gains the most
The critics' best arguments — and why they don't change the conclusion
"The vaccine doesn't match the circulating strains every year." True, and in mismatch years effectiveness is lower. But even a 20–30% effective vaccine in a mismatch year prevents tens of thousands of hospitalizations across the population, and partial immunity still moderates severity. The mismatch risk is real; it's a reason to advocate for better surveillance and formulation processes, not a reason to skip vaccination.
"I got the flu shot and still got flu." Also true and common. The vaccine is not a guarantee. But this conflates two separate questions: whether the vaccine prevents every individual case of flu, and whether it reduces population-level illness and serious outcomes. It does both, even if imperfectly.
"Natural immunity is better." Natural infection after flu does produce strong immunity to the specific strain you had. But it requires actually getting flu — which carries real costs in illness time, lost wages, and risk of complications. And flu strains drift every year, so last year's natural immunity doesn't fully protect against this year's circulating strain either.
The bottom line: For healthy adults, the flu shot is a modest-benefit, very-low-risk intervention. For older adults, pregnant women, young children, and people with chronic conditions, it's among the most impactful preventive health steps available each fall. The "only 50% effective" framing obscures more than it reveals.